Media | Contact us
SEARCH:
Bavarian Nordic

Search

Your search Nih returned about 9 results:

Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine

Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine COPENHAGEN, Denmark, July 27, 2016 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the initiation of a Phase 1 clinical trial of MVA-BN YF, a new vaccine candidate based on the Company’s proprietary MVA-BN platform, designed to protect against yellow fever virus. The study is spon...

Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million

Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of USD 160 million. Bavarian Nordic was awarded the PRV in February 2025, following the approval by the U.S. Food and Drug Adm...

Bavarian Nordic Publishes Annual Report 2024

Bavarian Nordic Publishes Annual Report 2024 Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million. Two new early-stage pipeline programs, Lyme disease and Epstein-Barr Virus (EBV), introduced. COPENHAGEN, Denmark, March 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2024. The consolidated, audited results were in line wit...

Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa

Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa The advance purchase agreement (APA) will be funded by Gavi’s First Response Fund, a mechanism created after the COVID-19 pandemic to ensure rapid access to scarce vaccine supplies in future health emergencies. Availability of all 500,000 doses has been secured for 2024. COPENHAGEN, Denmark and ...

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine First mpox vaccine to obtain prequalification by the WHO Approval will help accelerate access to the vaccine for all African countries COPENHAGEN, Denmark, September 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Company has obtained prequalification from the World Health Organization (WHO) for IMVANEX® (MVA-BN®)...

Bavarian Nordic Announces Submission of European Marketing Authorisation Applications for Investigational Ebola Vaccine Regimen

Bavarian Nordic Announces Submission of European Marketing Authorisation Applications for Investigational Ebola Vaccine Regimen COPENHAGEN, Denmark, November 7, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that its partner Janssen Pharmaceutical Companies of Johnson & Johnson have submitted Marketing Authorisation Applications (MAAs) to the European Medicines Agency (EMA)...

Bavarian Nordic Announces U.S. FDA Approval of JYNNEOS™ (Smallpox and Monkeypox Vaccine, Live, Non-replicating) for Prevention of Smallpox and Monkeypox Disease in Adults

Bavarian Nordic Announces U.S. FDA Approval of JYNNEOS™ (Smallpox and Monkeypox Vaccine, Live, Non-replicating) for Prevention of Smallpox and Monkeypox Disease in Adults First FDA approved non-replicating smallpox vaccine Only FDA approved vaccine for prevention of monkeypox Company granted Priority Review Voucher Conference call and webcast tomorrow at 3:00 PM CEST COPENHAGEN, Denmark, Septemb...

Bavarian Nordic Announces USD 100 Million Supply Contract for IMVAMUNE Smallpox Vaccine with the U.S. Government

Bavarian Nordic Announces USD 100 Million Supply Contract for IMVAMUNE Smallpox Vaccine with the U.S. Government New order affirms the U.S. Government commitment to freeze-dried IMVAMUNE  COPENHAGEN, Denmark, May 19, 2016 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Hea...

Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus Vaccine

Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus Vaccine Total considerations of up to USD 83 million with the majority secured for Phase 2 development of the multivalent MVA-BN® WEV vaccine candidate, in addition to options for Phase 3 preparatory work COPENHAGEN, Denmark, December 23...